Sorafenib is an oral multikinase inhibitor that inhibits tumor growth and proliferation by interfering with several receptor tyrosine kinases involved in the pathogenesis and perpetuation of ...

Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...

With his research group "Chromatin and SUMO Physiology," the molecular biologist has shown that the chemotherapeutic agent sorafenib actively remodels skeletal muscle cells and thus triggers cachexia.

The CHMP recommends approval of Bristol Myers' Opdivo plus Yervoy for the first-line treatment of hepatocellular carcinoma ...

1 For overall survival (OS), the combination of nivolumab plus ipilimumab showed a significant improvement in median OS compared with lenvatinib (Lenvima) or sorafenib (Nexavar) at 23.7 vs 20.6 months ...

Dana Walker, vice president, Opdivo global programme lead, BMS, said: “HCC is the predominant type of liver cancer globally, including in the EU, and when diagnosed at the advanced or unresectable ...

在其他近期新闻中,百时美施贵宝取得了重大进展。该公司已成功完成其药物Sotyktu治疗活动性银屑病关节炎的Phase 3试验,标志着在风湿病治疗领域取得重大进展。公司还获得了欧盟委员会的批准,将Opdivo和Yervoy用作某些类型结直肠癌的一线治疗 ...

The importance of FGF19-FGFR4 signaling is well-characterized in HCC. It has been reported that the activation of FGF19-FGFR4 signaling is important in multiple tyrosine kinase inhibitor (TKI), ...